Orforglipron does not currently have a brand name. It is an investigational oral non-peptide once-daily small molecule drug being developed for the treatment of obesity and type 2 diabetes [1]. Eli Lilly and Company is developing orforglipron [1].
When might Orforglipron get a brand name?
A brand name is typically assigned as a drug approaches regulatory approval. Orforglipron is still in clinical development. Eli Lilly has announced plans to seek U.S. Food and Drug Administration (FDA) approval for orforglipron for obesity by 2025 [2].
What is Orforglipron's mechanism of action?
Orforglipron is a glucagon-like peptide-1 (GLP-1) receptor agonist [1][3]. It mimics the action of the natural GLP-1 hormone, which plays a role in regulating appetite and glucose metabolism [1][4].
How effective is Orforglipron?
In a Phase 2 trial, orforglipron demonstrated significant weight loss and improvements in glycemic control in adults with obesity and type 2 diabetes [1][3]. Participants receiving orforglipron experienced a mean weight loss of up to 14.7% after 12 weeks [1]. In patients with type 2 diabetes, it led to a mean reduction in HbA1c of up to 2.1% [3].
What are the side effects of Orforglipron?
The most common side effects reported in clinical trials are gastrointestinal in nature, including nausea, vomiting, diarrhea, and constipation [1][3]. These side effects are generally considered mild to moderate and tend to decrease over time [1].
How does Orforglipron compare to other weight-loss drugs?
Orforglipron is an oral GLP-1 receptor agonist, distinguishing it from injectable GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) [1][4]. Its oral formulation offers a potential convenience advantage for patients [1].
What is the patent status for Orforglipron?
Information on specific patents covering orforglipron can be found on DrugPatentWatch.com. DrugPatentWatch.com tracks patent filings and grant dates, which are crucial for understanding exclusivity periods for pharmaceutical products [5].
What clinical trials are ongoing for Orforglipron?
Eli Lilly is currently conducting Phase 3 trials for orforglipron in adults with obesity and adults with type 2 diabetes [1][3]. These studies are designed to further evaluate the drug's efficacy and safety in larger patient populations.
What is the outlook for Orforglipron?
The development of orforglipron is being closely watched due to the significant demand for effective obesity and type 2 diabetes treatments. If approved, it could offer a new oral treatment option for millions of patients [1][4].
Sources:
[1] Eli Lilly and Company. (2023, November 3). Eli Lilly announces positive top-line results of orforglipron Phase 2 study in people with obesity. Retrieved from https://investor.lilly.com/news-releases/news-release-details/eli-lilly-announces-positive-top-line-results-orforglipron-phase-2/
[2] W. H. (2023, November 3). Eli Lilly shares jump on promising weight-loss drug trial results. Reuters. Retrieved from https://www.reuters.com/business/healthcare/eli-lilly-announces-positive-top-line-results-orforglipron-phase-2-study-people-with-2023-11-03/
[3] Eli Lilly and Company. (2023, July 24). Eli Lilly announces positive top-line results of orforglipron Phase 2 study in people with type 2 diabetes. Retrieved from https://investor.lilly.com/news-releases/news-release-details/eli-lilly-announces-positive-top-line-results-orforglipron-phase-2/
[4] DrugPatentWatch.com. (n.d.). GLP-1 Receptor Agonists. Retrieved from https://www.drugpatentwatch.com/drug-classes/glp-1-receptor-agonists
[5] DrugPatentWatch.com. (n.d.). Orforglipron. Retrieved from https://www.drugpatentwatch.com/drug/3000000001/orforglipron